Anecortave Acetate Risk-Reduction Trial (AART)

Stopped early · Phase 3 · Has a placebo group

Conditions studied: Dry AMD

In brief

A 48 month study of posterior juxtascleral administrations of Anecortave Acetate 15 or 30 mg or sham administration every 6 months.

Key facts

Study ID

NCT00307398

Run by

Alcon Research

People needed

2596

Starts

2004-03-01

Expected to finish

2009-01-01

Last updated by the study team

2012-11-28

Who can join

Age: 50 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Dry AMD study eye, Wet AMD non-study eye.
• Other protocol-defined inclusion criteria may apply.

You may not qualify if…

• Age
• Other protocol-defined exclusion criteria may apply.

Where it is running

• Study Centers in the United States and Globally — Fort Worth, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.